Glass House Brands (GLAS) Total Non-Current Liabilities (2020 - 2026)

Glass House Brands' (GLAS) quarterly Total Non-Current Liabilities came in at $111.9 million in Q1 2026, little changed year-on-year from $111.8 million in Q1 2025, and up 5.08% on a QoQ basis from $106.5 million in Q3 2025.

Glass House Brands (GLAS) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends

Glass House Brands (GLAS) has 7 years of Total Non-Current Liabilities data on file, last reported at $111.9 million in Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities changed 0.09% year-over-year to $111.9 million in Q1 2026; TTM through Mar 2026 was $111.9 million, a 0.09% change from a year earlier, with the FY2024 full-year figure at $234000.0, down 1.68% from the prior year.
  • Total Non-Current Liabilities for Q1 2026 stood at $111.9 million, up from $106.5 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for GLAS reached as high as $31122.5 billion in Q3 2022 and fell as low as $234000.0 in Q4 2024.
  • Historically, Total Non-Current Liabilities has averaged $2196.7 billion across 5 years, with a median of $112.9 million in 2025.
  • Across the five-year window, Total Non-Current Liabilities soared 117558753.43% in 2022 and slumped 100.0% in 2024, its largest moves.
  • Year by year, Total Non-Current Liabilities stood at $241373.0 in 2022, then fell by 1.4% to $238000.0 in 2023, then decreased by 1.68% to $234000.0 in 2024, then jumped by 45396.15% to $106.5 million in 2025, then increased by 5.08% to $111.9 million in 2026.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $111.9 million in Q1 2026, $106.5 million in Q3 2025, and $114.0 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - 14.92 Bn
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn 18.28 Bn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn 11.64 Bn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn 33.47 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn 599.10 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn - 1.86 Mn
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn 20.09 Bn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn 1.24 Bn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn 6.26 Bn
10 Glass House Brands 873.84 Mn 845.91 Mn 10.02 Mn 111.87 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 111.87 Mn
Sep 30, 2025 106.46 Mn
Jun 30, 2025 114.01 Mn
Mar 31, 2025 111.77 Mn
Dec 31, 2024 234,000.00
Sep 30, 2024 142.81 Mn
Jun 30, 2024 152.54 Mn
Mar 31, 2024 160.38 Mn
Dec 31, 2023 238,000.00
Sep 30, 2023 4,023.83 Bn
Jun 30, 2023 142.62 Mn
Mar 31, 2023 132.95 Mn
Dec 31, 2022 241,373.00
Sep 30, 2022 31,122.53 Bn
Jun 30, 2022 98.40 Mn
Mar 31, 2022 65.28 Mn
Dec 31, 2021 104.20 Mn
Sep 30, 2021 26.47 Mn
Mar 31, 2021 479.73 Mn
Dec 31, 2020 456.33 Mn